PTEN loss and ERBB2/ERBB3-mediated AKT reactivation drive resistance to MET inhibition in MET-amplified hepatocellular carcinoma
Open Access
- 24 September 2025
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1711-1724
Abstract
Background Hepatocellular carcinoma (HCC) remains a therapeutic challenge due to limited treatment options and frequent resistance to targeted therapies. MET amplification is a promising therapeutic target in a subset of HCC. However, mechanisms of resistance to MET inhibitors are not fully understood, impeding the efficacy of treatments. Methods We performed a genome-wide CRISPR-Cas9 screen to identify genetic determinants of resistance to MET inhibitors. The efficacy of selective MET inhibitors, including capmatinib and tepotinib, was evaluated in MET-amplified HCC models. Mechanistic studies were conducted to characterize AKT signaling dynamics and tumour cell responses under various treatment conditions. Results MET inhibitors selectively suppressed tumour growth in MET-amplified HCC. However, PTEN deficiency sustained AKT activation despite MET blockade, facilitating tumour survival. Moreover, MET inhibitor treatment triggered adaptive upregulation of ERBB2/ERBB3, leading to AKT reactivation and resistance. Combined inhibition of MET and AKT or ERBB kinases synergistically restored therapeutic response and induced apoptosis. These resistance mechanisms also reduced the efficacy of cabozantinib. Notably, neither combination was effective in MET-high non-amplified HCC. Conclusion Our study identifies PTEN deficiency and ERBB2/ERBB3-mediated reactivation as key resistance mechanisms to MET inhibition in MET-amplified HCC. The findings support biomarker-informed combination strategies and underscore the importance of stratifying patients based on MET amplification status.Keywords
Funding Information
- Shanghai Municipal Health Commission (2022YQ071)
- National Natural Science Foundation of China (82303948, 81902673, 82102923)
- Shanghai Jiao Tong University Foundation (24X010301428)
- Key laboratory of the Ministry of Education Foundation (SHSMU-ZLCX20211602)
This publication has 61 references indexed in Scilit:
- Overcoming MET-targeted drug resistance in MET-amplified lung cancer by aurora kinase B inhibitionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2025
- Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomachCellular Oncology, 2023
- Refining patient selection of MET-activated non-small cell lung cancer through biomarker precisionCancer Treatment Reviews, 2022
- Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinomaJournal of Hepatology, 2022
- Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to OsimertinibJAMA Oncology, 2018
- Cabozantinib: A Multitargeted Oral Tyrosine Kinase InhibitorPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2018
- Recent developments of c‐Met as a therapeutic target in hepatocellular carcinomaHepatology, 2017
- Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)Investigational New Drugs, 2015
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3Cell Reports, 2014
- Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumorsThe Journal of Clinical Pharmacology, 2013